India to Saudi Arabia: Ketorolac Export Trade Route

The India to Saudi Arabia Ketorolac corridor is one of India's established pharmaceutical export routes, with 15 shipments documented worth a combined $827.8K USD. The route is dominated by GLAND PHARMA LTD, which alone accounts for roughly 66% of all export value, reflecting the consolidated nature of India's ketorolac manufacturing sector.

Across 6 active suppliers, the average shipment value stands at $55.2K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 83% of all shipments, consistent with ketorolac's non-urgent bulk-order profile.

Shipment activity peaks during January–March, with an average transit time of 34 days port-to-port. The route has recorded an annual growth rate of 10.3%, placing it at rank #14 among India's top ketorolac export destinations globally.

On the import side, key buyers of Indian ketorolac in Saudi Arabia include BOSTON ONCOLOGY ARABIA, PHARMA PHARMACEUTICALS INDUSTRIES, CiGALAH MEDICAL COM and 3 others. BOSTON ONCOLOGY ARABIA is the single largest importer with 8 shipments valued at $758.2K USD.

India's ketorolac exports to Saudi Arabia are driven primarily by a handful of large-scale manufacturers. GLAND PHARMA LTD with 7 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 6 active exporters signals a competitive but concentrated market — buyers in Saudi Arabia benefit from supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — GLAND PHARMA LTD, GLAND PHARMA LIMITED, STERIL-GENE LIFE SCIENCES PRIVATE LIMITED — together account for 100% of total trade value on this route. The average shipment value of $55.2K USD reflects primarily bulk commercial orders from large pharmaceutical distributors.

Beyond the primary product category, shipments on this route include closely related formulations such as ketorolac tromethamine injection 60mg 2ml 30mg ml and ketorolac tromethamine injection 60mg/2ml (30mg/ml), suggesting that buyers in Saudi Arabia tend to consolidate orders across related product lines from the same Indian supplier.

On the buying side, BOSTON ONCOLOGY ARABIA is the largest importer with 8 shipments worth $758.2K USD — representing 92% of all ketorolac imports from India on this route. A total of 6 buyers are active on this corridor.